| 2026-04-01 |
详情>>
股本变动：
变动后总股本1157.44万股
|
| 2026-04-01 |
详情>>
业绩披露：
2025年年报每股收益-0.05美元,归母净利润-56.9万美元,同比去年增长73.91%
|
| 2025-12-23 |
详情>>
内部人交易：
Thompson Tommy G股份增加8400.00股
|
| 2025-11-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.01美元,归母净利润5.00万美元,同比去年增长102.06%
|
| 2025-11-03 |
股东大会：
将于2025-12-15召开股东大会
会议内容 ▼▲
- 1.To elect directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2024 (“say-on-pay”);
3.To provide a non-binding advisory vote on the frequency of future non-binding advisory votes on the compensation of our named executive officers (“say-on-frequency”);
4.To ratify the appointment of Berkowitz Pollack Brant Advisors + CPAs, LLP (“Berkowitz Pollack Brant”), an independent registered public accounting firm, as the independent auditor of our Company for the fiscal year ending December 31, 2025;
5.To approve an amendment to our Amended and Restated Articles of Incorporation, as amended, to increase the number of authorized shares of common stock, $0.001 par value per share, to 640,000,000 shares;
6.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2025-08-12 |
详情>>
业绩披露：
2025年中报每股收益-0.01美元,归母净利润-10.2万美元,同比去年增长94.41%
|
| 2025-05-13 |
详情>>
业绩披露：
2025年一季报每股收益-0.06美元,归母净利润-65.3万美元,同比去年增长11.04%
|
| 2025-03-27 |
详情>>
业绩披露：
2024年年报每股收益-0.19美元,归母净利润-218.1万美元,同比去年增长78.78%
|
| 2025-01-03 |
复牌提示：
2025-01-03 09:32:33 停牌，复牌日期 2025-01-03 09:37:33
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.21美元,归母净利润-243.3万美元,同比去年增长74.10%
|
| 2024-10-25 |
股东大会：
将于2024-12-05召开股东大会
会议内容 ▼▲
- 1.To elect directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2023 (“say-on-pay”);
3.To ratify the appointment of Berkowitz Pollack Brant Advisors + CPAs, LLP (“Berkowitz Pollack Brant”), an independent registered public accounting firm, as the independent auditor of our Company for the fiscal year ending December 31, 2024;
4.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2024-08-12 |
详情>>
业绩披露：
2024年中报每股收益-0.16美元,归母净利润-182.4万美元,同比去年增长69.69%
|
| 2024-05-10 |
详情>>
业绩披露：
2024年一季报每股收益-0.06美元,归母净利润-73.4万美元,同比去年增长79.63%
|
| 2024-03-29 |
详情>>
业绩披露：
2023年年报每股收益-0.98美元,归母净利润-1027.8万美元,同比去年增长-109.18%
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.92美元,归母净利润-939.5万美元,同比去年增长-127.39%
|
| 2023-05-17 |
股东大会：
将于2023-06-26召开股东大会
会议内容 ▼▲
- 1.To elect directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2022 (“say-on-pay”);
3.To approve an amendment to our Amended and Restated Articles of Incorporation, as amended, to increase the number of authorized shares of common stock, $0.001 par value per share, from 12,000,000 shares to 32,000,000 shares;
4.To approve, pursuant to Nasdaq Rules 5635(b) and 5635(d), the issuance of up to 5,000,000 shares of the Company’s common stock to be sold in one or more private placements to Rubric Capital Management LP (“Rubric”) or one or more of its affiliates, under a subscription agreement with Rubric;
5.To ratify the appointment of Grant Thornton LLP, an independent registered public accounting firm, as the independent auditor of our Company for the fiscal year ending December 31, 2023;
6.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2022-08-15 |
财报披露：
美东时间 2022-08-15 盘前发布财报
|
| 2022-04-27 |
详情>>
拆分方案：
每50.0000合并分成1.0000股
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-14 |
股东大会：
将于2021-05-27召开股东大会
会议内容 ▼▲
- 1.To elect directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2020 (“say-on-pay”);
3.To approve a stock option exchange program for those employees of the company who are not named executive officers;
4.To approve an amendment to the TherapeuticsMD, Inc. 2019 Stock Incentive Plan (the “2019 Plan”) to increase the number of authorized shares thereunder;
5.To ratify the appointment of Grant Thornton LLP, or Grant Thornton, an independent registered public accounting firm, as the independent auditor of our company for the fiscal year ending December 31, 2021;
6.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2020-05-04 |
股东大会：
将于2020-06-18召开股东大会
会议内容 ▼▲
- 1.To elect directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2019 (“say-on-pay”);
3.To approve an amendment to our Amended and Restated Articles of Incorporation, as amended, to increase the number of authorized shares of common stock, $0.001 par value per share, from 350,000,000 shares to 600,000,000 shares;
4.To approve the TherapeuticsMD, Inc. 2020 Employee Stock Purchase Plan;
5.To ratify the appointment of Grant Thornton LLP, or Grant Thornton, an independent registered public accounting firm, as the independent auditor of our company for the fiscal year ending December 31, 2020;
6.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2019-04-30 |
股东大会：
将于2019-06-20召开股东大会
会议内容 ▼▲
- 1.To elect directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2018 (“say-on-pay”);
3.To provide a non-binding advisory vote on the frequency of future non-binding advisory votes on the compensation of our named executive officers (“say-on-frequency”);
4.To approve the TherapeuticsMD, Inc. 2019 Stock Incentive Plan (“Stock Incentive Plan”);
5.To ratify the appointment of Grant Thornton LLP, or Grant Thornton, an independent registered public accounting firm, as the independent auditor of our company for the fiscal year ending December 31, 2019;
6.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2018-04-27 |
股东大会：
将于2018-06-25召开股东大会
会议内容 ▼▲
- 1.To elect directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2017 (“say-on-pay”);
3.To ratify the appointment of Grant Thornton LLP, or Grant Thornton, an independent registered public accounting firm, as the independent auditor of our company for the fiscal year ending December 31, 2018;
4.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2017-04-25 |
股东大会：
将于2017-06-16召开股东大会
会议内容 ▼▲
- 1.To elect directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2016 (“say-on-pay”);
3.To ratify the appointment of Grant Thornton LLP, or Grant Thornton, an independent registered public accounting firm, as the independent auditor of our company for the fiscal year ending December 31, 2017;
4.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2016-04-28 |
股东大会：
将于2016-06-16召开股东大会
会议内容 ▼▲
- 1. To elect directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified;
2. To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2015 (“say-on-pay”);
3. To ratify the appointment of Grant Thornton LLP, or Grant Thornton, an independent registered public accounting firm, as the independent auditor of our company for the fiscal year ending December 31, 2016;
4. To transact such other business as may properly come before the meeting or any adjournment thereof.
|